Drugs /
ec1456
Overview
Clinical Trials
Ec1456 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating ec1456, 1 is phase 1 (0 open).
ER Negative, ER No Expression, and FOLR1 Expression are the most frequent biomarker inclusion criteria for ec1456 clinical trials.
Breast carcinoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in ec1456 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.